Alain Ravaud

44.3k citations

368 papers · 17.8k indexed · 9 hit papers · h-index 59

Impact in

Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
Pulmonary and Respiratory Medicine top 0.05%
- Renal cell carcinoma treatment

Papers in

Pulmonary and Respiratory Medicine 254
- Renal cell carcinoma treatment 207
Cancer Research 98
- Cancer Genomics and Diagnostics 92

Co-authors: Bernard Escudier Sergio Bracarda Robert J. Motzer Stéphane Oudard Christine Chevreau Sylvie Négrier Camillo Porta Thomas E. Hutson
Journals: Journal of Clinical Oncology (87 papers)Annals of Oncology (41 papers)European Journal of Cancer (19 papers)Clinical Genitourinary Cancer (8 papers)Cancer Treatment Reviews (8 papers)
Partner nations: France United States Italy

In The Last Decade

Alain Ravaud

353 papers receiving 17.5k citations

Hit Papers

9 papers align trajectories log scale

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma 2024 · 74 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 Annals of Oncology
2021 Annals of Oncology
2017 Journal of Clinical Oncology
2017 The Lancet Oncology
2010 Cancer
2010 Journal of Clinical Oncology
2008 The Lancet
2007 The Lancet
1998 New England Journal of Medicine

Peers

Countries citing papers authored by Alain Ravaud

Since Specialization

Citations

This map shows the geographic impact of Alain Ravaud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain Ravaud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain Ravaud more than expected).

Fields of papers citing papers by Alain Ravaud

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alain Ravaud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain Ravaud. The network helps show where Alain Ravaud may publish in the future.

Co-authors

The 25 scholars most cited alongside Alain Ravaud, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alain Ravaud Line = papers co-authored together Alain Ravaud links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma Journal for ImmunoTherapy of Cancer ·G. Korovinska, Nathalie Rioux‐Leclercq, Maxime Meylan, Zahra Yamin, Christophe Passot, U Patassini, Ronan Flippot, Gaëlle Fromont, Gwénaëlle Gravis, Lionnel Geoffrois, Christine Chevreau, Frédéric Rolland, Ellen Blanc, Jeong Sang Lee, Alain Ravaud, Y Yu, Bernard Escudier, Sylvie Négrier, Laurence Albigès	2023	8
2	Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review European Journal of Cancer ·Mathieu Larroquette, Charlotte Domblides, Jeong Sang Lee, Gary Barney, Amandine Quivy, Amanda Dall’Agnol Dal Magro, Amanda Hinkle, Marine Gross‐Goupil, Alain Ravaud, Amaury Daste	2021	53
3	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial European Urology ·Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Bernard Escudier, Frede Donskov, Robert D. Hawkins, Sergio Bracarda, Jens Bedke, Ugo De Giorgi, Camillo Porta, Alain Ravaud, Francis Parnis, Enrique Grande, Wei Zhang, Mahrukh Huseni, Susheela Carroll, Roxana I. Sufan, Christina Schiff, Michael B. Atkins	2020	60
4	Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis Clinical Cancer Research ·Daniel J. George, Jean-François Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, Sherry Li, Michelle Casey, Olga Valota, Brigitte Laguerre, Allan J. Pantuck, Hardev Pandha, Anup Patel, Carol S. T. Li, Alain Ravaud	2018	18
5	Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Clinical Cancer Research ·Brian I. Rini, Bernard Escudier, Jean-François Martini, Ahmed Magheli, Christer Svedman, Margarita Lopatin, Dejan Knezevic, Audrey D. Goddard, Phillip G. Febbo, Rachel Li, Xun Lin, Olga Valota, Michael Staehler, Robert J. Motzer, Alain Ravaud	2018	45
6	Treatment of spinal metastases in renal cell carcinoma: A critical review Critical Reviews in Oncology/Hematology ·玲子吉地, Marine Gross‐Goupil, Charlotte Domblides, Andri Rifa'i Nim., Vincent Pointillart, Amaury Daste, Olivier Hauger, Alain Ravaud	2018	12
7	Immune checkpoint inhibitors and elderly people: A review European Journal of Cancer ·Amaury Daste, Charlotte Domblides, Marine Gross‐Goupil, Camille Chakiba, Amandine Quivy, 遠山友紀子, Erwan de Monès, Nicolas Larmonier, Pierre Soubeyran, Alain Ravaud	2017	139
8	Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature Clinical Genitourinary Cancer ·Amanda Hinkle, Marine Gross‐Goupil, Mathiéu Molimard, 遠山友紀子, Alain Ravaud, Amaury Daste	2017	2
9	PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT Clinical Pharmacology & Therapeutics ·Christian Rolfo, Judith de Vos‐Geelen, Nicolás Isambert, L Rhoda Molife, Jan H.M. Schellens, Jacques De Grève, Jean‐Yves Blay, L. Dirix, Márton Sulyok, Antoîne Italiano, Guy Jérusalem, Thijs Delnoij, Karin Leunen, Morten Mau‐Sørensen, Ruth Plummer, Maria Learoyd, Nigel Baker, Anitra Fielding, Alain Ravaud	2017	1
10	Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature Clinical Genitourinary Cancer ·Amaury Daste, Marine Gross‐Goupil, Amandine Quivy, Nicole Helle, Jean‐Christophe Bernhard, Alain Ravaud	2016	1
11	Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer Clinical Cancer Research ·Bernard Escudier, Viktor Grünwald, Alain Ravaud, Yen‐Chuan Ou, Daniel Castellano, Chia‐Chi Lin, Jürgen E. Gschwend, Andrea Harzstark, S Lustgarden, Nicoletta Pirotta, Matthew Squires, Michael Shi, Eric Angevin	2014	49
12	Functional Decline in Older Patients With Cancer Receiving First-Line Chemotherapy Journal of Clinical Oncology ·Stéphanie Hoppe, M. Rainfray, Marianne Fonck, Dott. Giovanni Vailati, Jean‐Frédéric Blanc, J. Ceccaldi, C. Mertens, C. Blanc-Bisson, Y. Imbert, Laurent Cany, Kaede Inagaki, Jérôme Dauba, Nadine Houédé, Carine Bellera, Anne Floquet, Michel Betrencourt, Alain Ravaud, Camille Chakiba, Simone Mathoulin‐Pélissier, Pierre Soubeyran	2013	174
13	Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer Journal of Clinical Oncology ·Pierre Soubeyran, Marianne Fonck, C. Blanc-Bisson, Jean‐Frédéric Blanc, J. Ceccaldi, C. Mertens, Y. Imbert, Laurent Cany, Kaede Inagaki, Jérôme Dauba, Francis Andriamampionona, Nadine Houédé, Anne Floquet, François Chomy, Véronique Brouste, Alain Ravaud, Carine Bellera, M. Rainfray	2012	305
14	RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RECORD-2 Annals of Oncology ·Alain Ravaud, Carlos H. Barrios, Oezlem Anak, Diana Pelov, Fei Gao, B. Yа. Alekseev, Tattersall Mh, Sanjiv S. Agarwala, Sıddika Songül Yalçın, Bohuslav Melichar	2012	24
15	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial The Lancet ·Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud Hit paper breakdown →	2008	2339
16	Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma Journal of Clinical Oncology ·Toni K. Choueiri, A. Plantade, Paul Elson, Sylvie Négrier, Alain Ravaud, Stéphane Oudard, Ming Zhou, Brian I. Rini, Ronald M. Bukowski, Bernard Escudier	2007	311
17	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial The Lancet ·Bernard Escudier, A Płużańska, P. Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, M. Filipek, Bohuslav Melichar, Emilio Bajetta, В. А. Горбунова, Jacques‐Olivier Bay, I. Bodrogi, Agnieszka Jagiełło-Gruszfeld, N. Moore Hit paper breakdown →	2007	1722
18	A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma British Journal of Cancer ·Alain Ravaud, E. Legrand, M. Delaunay, E Bussières, Vincent Coulon, Laurent Cany, Sylvie Huet, Doris Ortner, Michèle Kind, François Chomy, M. Carmen Valdes Hevia Temprano, N. Gualde	1995	19
19	Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma British Journal of Cancer ·Alain Ravaud, Sylvie Négrier, Laurent Cany, Yacine Merrouche, M. Le Guillou, Jean‐Yves Blay, M. Clavel, Richard Gastón, R. Oskam, Thierry Philip	1994	31
20	Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. Gut ·Paul Calès, Hervé Desmorat, J.P. Vinel, J. P. Caucanas, Alain Ravaud, Sulamanidze Marlen, Sibel Huban, Jean‐Pierre Pascal	1990	149

About Alain Ravaud

Alain Ravaud is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Biological Psychiatry and Molecular Biology, having authored 368 papers that have together received 17.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (207 papers), Renal and related cancers (96 papers), Cancer Genomics and Diagnostics (92 papers), Cancer Immunotherapy and Biomarkers (72 papers), Bladder and Urothelial Cancer Treatments (65 papers), Urinary and Genital Oncology Studies (27 papers), Colorectal Cancer Treatments and Studies (26 papers) and Economic and Financial Impacts of Cancer (24 papers). The work is most often cited by research in Cancer Research (4.8k citations), Pulmonary and Respiratory Medicine (10.4k citations), Biological Psychiatry (751 citations), Oncology (6.8k citations) and Behavioral Neuroscience (584 citations). Alain Ravaud has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Bernard Escudier, Sergio Bracarda, Robert J. Motzer, Stéphane Oudard, Christine Chevreau, Sylvie Négrier, Camillo Porta, Thomas E. Hutson, Viktor Grünwald and Robert Dantzer. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Clinical Genitourinary Cancer and Cancer Treatment Reviews.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact